Oncotarget

Reviews:

This article has been corrected. Correction in: Oncotarget. 2018; 9:19460.

Role of novel histone modifications in cancer

Muthu K. Shanmugam, Frank Arfuso, Surendar Arumugam, Arunachalam Chinnathambi, Bian Jinsong, Sudha Warrier, Ling Zhi Wang, Alan Prem Kumar, Kwang Seok Ahn, Gautam Sethi and Manikandan Lakshmanan _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:11414-11426. https://doi.org/10.18632/oncotarget.23356

Metrics: PDF 2968 views  |   HTML 7008 views  |   ?  


Abstract

Muthu K. Shanmugam1, Frank Arfuso2, Surendar Arumugam10, Arunachalam Chinnathambi3, Bian Jinsong1, Sudha Warrier4, Ling Zhi Wang1,5, Alan Prem Kumar1,5,6,7,8, Kwang Seok Ahn9, Gautam Sethi1 and Manikandan Lakshmanan10,11

1 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

2 Stem Cell and Cancer Biology Laboratory, School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia

3 Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia

4 Division of Cancer Stem Cells and Cardiovascular Regeneration, School of Regenerative Medicine, Manipal Academy of Higher Education (MAHE), Bangalore, India

5 Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

6 Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA, Australia

7 National University Cancer Institute, National University Health System, Singapore, Singapore

8 Department of Biological Sciences, University of North Texas, Denton, Texas, USA

9 College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul, Korea

10 Institute of Molecular and Cell Biology, A*STAR, Biopolis Drive, Proteos, Singapore, Singapore

11 Department of Pathology, National University Hospital Singapore, Singapore, Singapore

Correspondence to:

Manikandan Lakshmanan, email:

Gautam Sethi, email:

Kwang Seok Ahn, email:

Keywords: cancer; histones; oncogenes; tumor suppressor genes; ubiquitination

Received: October 11, 2017 Accepted: December 01, 2017 Published: December 17, 2017

Abstract

Oncogenesis is a multistep process mediated by a variety of factors including epigenetic modifications. Global epigenetic post-translational modifications have been detected in almost all cancers types. Epigenetic changes appear briefly and do not involve permanent changes to the primary DNA sequence. These epigenetic modifications occur in key oncogenes, tumor suppressor genes, and transcription factors, leading to cancer initiation and progression. The most commonly observed epigenetic changes include DNA methylation, histone lysine methylation and demethylation, histone lysine acetylation and deacetylation. However, there are several other novel post-translational modifications that have been observed in recent times such as neddylation, sumoylation, glycosylation, phosphorylation, poly-ADP ribosylation, ubiquitination as well as transcriptional regulation and these have been briefly discussed in this article. We have also highlighted the diverse epigenetic changes that occur during the process of tumorigenesis and described the role of histone modifications that can occur on tumor suppressor genes as well as oncogenes, which regulate tumorigenesis and can thus form the basis of novel strategies for cancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23356